Abstract | OBJECTIVE: DESIGN: Follow-up study. SETTING: Tertiary care hospital. PARTICIPANTS: INTERVENTION: MAIN OUTCOME MEASURES: The incidence of allergic and infectious diseases during the first year of life, as assessed by means of validated questionnaires. RESULTS: Seventy-seven of 90 infants (86%) participated in the follow-up study. Baseline patient, maternal, and environmental characteristics did not differ between the glutamine-supplemented (n = 37) and control (n = 40) groups, except for the incidence of serious neonatal infections and child care attendance. After adjustment for confounding factors, the risk for atopic dermatitis was lower in the glutamine-supplemented group (odds ratio [OR], 0.13; 95% confidence interval [CI], 0.02-0.97). However, the incidence of bronchial hyperreactivity (OR, 0.34; 95% CI, 0.10-1.21) and infections of the upper respiratory (OR, 0.99; 95% CI, 0.35-2.79), lower respiratory (OR, 0.39; 95% CI, 0.13-1.24), and gastrointestinal (OR 1.25, 95% CI 0.23-6.86) tracts was not different between the treatment groups. CONCLUSIONS:
|
Authors | Anemone van den Berg, Annelies van Zwol, Henriëtte A Moll, Willem P F Fetter, Ruurd M van Elburg |
Journal | Archives of pediatrics & adolescent medicine
(Arch Pediatr Adolesc Med)
Vol. 161
Issue 11
Pg. 1095-101
(Nov 2007)
ISSN: 1538-3628 [Electronic] United States |
PMID | 17984413
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Bronchial Hyperreactivity
(epidemiology)
- Communicable Diseases
(epidemiology)
- Dermatitis, Atopic
(epidemiology)
- Enteral Nutrition
- Follow-Up Studies
- Glutamine
(administration & dosage)
- Humans
- Hypersensitivity
(epidemiology)
- Incidence
- Infant
- Infant, Newborn
- Infant, Premature
- Infant, Very Low Birth Weight
- Logistic Models
- Respiration, Artificial
(statistics & numerical data)
- Risk Assessment
|